Ultragenyx Pharmaceutical Inc. 8-K

What Happened
On February 12, 2026 Ultragenyx Pharmaceutical Inc. (RARE) filed an 8-K furnishing a press release with its financial results for the quarter and year ended December 31, 2025 (Item 2.02) and announced a strategic restructuring (Item 2.05). The company began a reduction-in-force (RIF) the same day affecting approximately 10% of its workforce (about 130 employees) and expects the RIF to be substantially completed in the first half of 2026. Ultragenyx estimates approximately $50 million of total restructuring-related charges, primarily ~ $10 million for employee severance and ~ $40 million related to termination of UX143 manufacturing agreements; it expects substantially all charges (and related cash payments) to be recognized and paid in H1 2026.

Key Details

• Filing date: February 12, 2026; press release covers quarter and year ended December 31, 2025 (Exhibit 99.1).
• Workforce cut: ~10% reduction, ~130 employees; notifications began Feb 12, 2026; substantially completed in H1 2026.
• Estimated charges: $50 million total — **$10M** severance/employee costs and ~$40M related to termination of UX143 manufacturing agreements.
• Timing: Company anticipates recognizing and paying substantially all charges during the first half of 2026; amounts are estimates and may change.

Why It Matters
These restructuring charges will likely affect Ultragenyx’s reported results and cash flow in the near term (H1 2026). The workforce reduction is intended to lower future operating expenses, but the filing cautions actual savings and the final amount/timing of charges may differ from estimates. The $40M related to terminating UX143 manufacturing agreements is a material, program-specific cost noted by the company and could affect the accounting and cash needs tied to that program. Investors should review the February 12 press release and monitor subsequent filings for the company’s detailed Q4/FY2025 results and any updates on restructuring outcomes.